Completed PHASE3 INTERVENTIONAL 2-arm NCT01408576

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus (EMBODY4)

A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects

Sponsor: UCB Pharma

Conditions Systemic Lupus Erythematosus

Interventions Epratuzumab

Updated 8 times since 2017 Last updated: Sep 3, 2018 Started: Jul 31, 2011 Primary completion: Feb 29, 2016 Completion: Feb 29, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Systemic Lupus Erythematosus, this trial is completed. The trial is conducted by UCB Pharma and has accumulated 8 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Nov 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Nov 2018 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB Pharma

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amarillo, United States , Ashkelon, Israel , Atlanta, United States , Aurora, United States , Austin, United States , Aventura, United States , Barcelona, Spain , Beersheba, Israel , Belo Horizonte, Brazil , Berlin, Germany and 182 more locations